AzTrials
AzTrials

PeriodontitisPhase 4NCT05834517

''Efficacy of Locally Delivered Hyaluronic Acid Gel as an Adjunctive to Non-Surgical Management of Periodontitis

A Phase 4 study testing Hyaluronic acid and non surgical periodontal therapy in people with Periodontitis, run by Ehab Haider Hassan El-emam at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and… Read more about this study

Who is it for?
Ages 25 to 55 years
Conditions the study is for
Periodontitis
What is being tested?
Hyaluronic acid and non surgical periodontal therapy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
28 participants
Where
1 siteEgypt
Study dates
2 May 2022to 10 Dec 2022
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • .Patients have to be free from any systemic disease as proven by Burket's oral medicine health history questionnaire (Glik et al., 2008).
  • .Both genders aged 20-55.
  • . Periodontitis (Stage II or stage III) Patients; (3-6 mm CAL ,pocket depth ≤7 mm, mostly horizontal 15%-33% bone loss as assessed by preoperative radiographs with no tooth loss due to periodontitis) (Tonetti et al., 2017).

Who cannot join

  • Pregnant lactating females
  • Smoking
  • Patients who can't be committed to oral hygiene instructions
  • History of periodontal surgery or antimicrobial therapy for at least 4 months.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Cairo

    Cairo

Other trials in Egypt

About this study

Official title: ''Efficacy of Locally Delivered Hyaluronic Acid Gel as an Adjunctive to Non-Surgical Management of Stage II or Stage III Periodontitis

Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and invasion. HA is released by many cells including fibroblasts (Dahiya et al., 2013).

Hyaluronic acid can be found in the skin, eyes and the periodontium. In addition, it appears in body fluids like serum, gingival crevicular fluid and saliva. Hyaluronic acid is created in the periodontium by HA synthase enzyme present in numerous cells like fibroblast and cementoblast (Fraser et al., 1997).

There is evidence that hyaluronic acid is bacteriostatic, fungostatic, anti-inflammatory, osteoconduvtive and pro-angiogenic. These dissimilar properties illustrate the ability of hyaluronic acid to be an ideal material for wound healing (Carlson et al., 2004).

Read the detailed description

Periodontitis is a chronic multifactorial inflammatory disease, associated with the dental plaque biofilms, its distinct feature is destruction of the tooth supporting apparatus. Its main features include: damage of the periodontal tissue, that's manifested by clinical attachment loss, alveolar bone loss, periodontal pocketing and bleeding gum (Armitage, 1999).

A new periodontitis classification scheme has been approved, in which forms of the disease previously known as "chronic" or "aggressive" are now gathered under a single term ("periodontitis") and are more characterized based on a multi-dimensional staging and grading system. Staging is basically reliant on the severity of disease as well as on the difficulty of disease management, on the other hand , grading offers additional information about biological aspects of the disease including a history-based analysis of the rate of periodontitis progression; risk assessment for further progression and analysis of likely poor outcomes of treatment (Caton et al., 2018; Papapanou et al., 2018).

Host-Microbial interaction is having a huge effect on the nature of periodontal disease progression. The microbial biofilm elicits the host to release inflammatory mediators that have a negative effect on the connective tissues. The biofilm or dental plaque is required but not enough to induce periodontitis, since it is the host inflammatory response to this microbial challenge that eventually can be the reason for destruction of the periodontium (Haffajee and Socransky, 1994; Page , 1997; Darveau, 2010).

Physical removal of dental plaque through debridement and/or using antimicrobial agents is the most prevalent management of periodontitis. Initially, scaling and root planing (SRP) is done with the means of hand or ultrasonic instruments to debride the root surface, allowing the development of a long junctional epithelium. Clinically, in case of lack of accessibility like extensive tissue loss, deep periodontal pocket and furcation involvement make it unclear to determine the efficacy of the debridement (Lindhe, 1985).

The use systemic antibiotics (ABs) can contribute in treatment goals without surgical treatment. However, their usage is limited to particular patients for those who have previously two courses of SRP with no improvement in periodontal pocket depth. Additionally, the side effects and rise in AB resistance over time have reduced the number of cases managed in this way (Walters et al., 2015).

Local antimicrobial therapy includes the direct placement of an antimicrobial agent into sub gingival sites, limiting the effect of the agent on non-oral body sites. The main goal in using an intra-pocket device for the delivery of an antibacterial agent is maintenance of therapeutic levels of the drug for the required period of time. This method has direct influence on the pathogens, without any damage to the tissues (Garg, 2015).

The first local drug delivery system in periodontal treatment was ActiciteTM. The first non resorbable system. Although quite effective, the delivery of this system in the periodontal pockets required extra skills and another visit to the dentist in order to be removed. The drawbacks of the non-resorbable systems headed to the advance of resorbable systems for antimicrobial delivery like ATRIDOXTM, gel containing 10 % doxycyline hyclate. Progresses in the formulation of local delivery systems lead to the manufacture of ARESTINTM, sustained release product consist of minocycline (Krayer et al., 2010).

Local delivery antibiotics that are commercially available as controlled release devices had many disadvantages including limited spectrum of antimicrobial activity in some periodontal polymicrobial infections, risk of generating antimicrobial resistance and massive acquisition cost (Sltos , 2002).

The most extensive used and studied antiseptic in oral diseases is chlorhexidine. Chlorhexidine displays high affinity towards bacteria .The highest advantages of chlorhexidine application after SRP or surgical periodontal treatment include better-quality in wound healing and general plaque control (Horz \& Conrads, 2007). However, even with the advantages, the application may end with staining of the teeth, taste disturbances and increase of calculus formation (Zanatta et al., 2010).

Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and invasion. HA is released by many cells including fibroblasts (Dahiya et al., 2013).

Hyaluronic acid can be found in the skin, eyes and the periodontium. In addition, it appears in body fluids like serum, gingival crevicular fluid and saliva. Hyaluronic acid is created in the periodontium by HA synthase enzyme present in numerous cells like fibroblast and cementoblast (Fraser et al., 1997).

There is evidence that hyaluronic acid is bacteriostatic, fungostatic, anti-inflammatory, osteoconduvtive and pro-angiogenic. These dissimilar properties illustrate the ability of hyaluronic acid to be an ideal material for wound healing (Carlson et al., 2004).

The anti-inflammatory action of hyaluronic acid is related to the role of exogenous Hyaluronan as a scavenger by draining metaloprotinases, prostaglandins and other bio-active molecules (Laurant et al., 1995). Moreover, hyaluronic acid is anti-edematous due to its osmotic activity. The high concentration of medium and lower molecular weight hyaluronic acid has a possible bacteriostatic role especially on aggregatibacter actinomyecetemcomitans and staph aureus strains which are usually found in periodontal wounds (Pirnazar et al., 1999).

In patients with chronic periodontitis, the adjunctive application of hyaluronic acid to non -surgical periodontal treatment including (scaling and root planning) results in much higher clinical improvement including probing depth and bleeding on probing (Bertl, 2015).

A clinical trial by (Yi Xu et al ., 2004) used HA gel as an adjunctive to scaling and root planning in treatment of chronic periodontitis , regarding the clinical parameters and microbiological analysis had revealed that HA gel has an essential role in improvement of all clinical parameters but in contrary, microbiological analysis using conventional PCR revealed that hyaluronic acid has no effect on the bacteria .

Based on the previously mentioned properties hyaluronic acid, We hypothesized that hyaluronic acid has a major role to be used as an adjunctive to non-surgical treatment in periodontitis patients.

Conditions
Periodontitis
Being tested
Hyaluronic acid, non surgical periodontal therapy
Medical subject headings
Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Hyaluronic acidDrug

    Also called hyaluronan

    Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and invasion. HA is released by many cells including fibroblasts

  • non surgical periodontal therapyProcedure or surgery

    NSPT, with or without adjunctive therapies, is an effective treatment for periodontitis. It reduces PD and results in formation of some new attachment; however, it also has several limitations, and surgical therapy might be required to control inflammation and optimize outcomes. When used for non-surgical scaling and root planing, periodontal curettes can reach a mean PD of up to approximately 5.5 mm. The mean PD in which a plaque-free and calculus-free surface can be established is <4 mm

Study groups in NCT05834517
Study groupRoleWhat they receive
hyaluronic acid/ scalingExperimentaltopical application of hyaluronic acid after scaling by 1 day
Receives: Drug: Hyaluronic acid; Procedure: non surgical periodontal therapy
scalingExperimentalscaling only
Receives: Procedure: non surgical periodontal therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. clinical score

    1-Plaque index (PI) 2. Sulcus bleeding index (BI) 3-Probing depth (PD) 4-Clinical attachment loss level (CAL)

    Measured: 3 months

Secondary outcomes (1)
  1. analyzing quantitative changes of pathogenic periodontal bacteria as a secondary objectives.

    using real time PCR for analyzing the bacterial loads of 1. Porphyromonus gingivalis 2. Aggregatibacter Actinomycetumomitans

    Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Apr 2023
  2. Study start2 May 2022
  3. Primary completion5 Dec 2022
  4. Study completion10 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
topical application of hyaluronic acid in patients with periodontitis 1 day after scaling
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
28 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05834517
Sponsor's protocol ID
FDASU-RECD125091
Status last verified
Apr 2023
First submitted
17 Apr 2023
Last updated
28 Apr 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Hyaluronic acid and non surgical periodontal therapy in people with Periodontitis, run by Ehab Haider Hassan El-emam at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

clinical score (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in